Conflict Of Interest Reform Fight Reignites Following Panel Revelations
This article was originally published in The Tan Sheet
Advisory committee conflict of interest reform draws increased attention in the wake of concerns raised about a recent Reproductive Health panel meeting.
You may also be interested in...
Adjusting advisory committee conflict of interest rules becomes a high-priority issue in reauthorizing FDA’s drug user fee program. With several bills proposing to loosen the rules, Sen. Hagan’s draft FDA reform legislation could bring the most changes.
Several fees for prescription drug, generic drug, and biosimilar applications are set to increase, although some also will drop.
The group will be called the Office of Therapeutic Products, but needs more people to handle its increasing workload.